Alvotech (ALVO) Capital Expenditures (2022 - 2026)
Alvotech (ALVO) posted Capital Expenditures of -$7.1 million for Q1 2026, down 105.94% on a QoQ basis from $120.2 million in Q4 2025, and up 69.2% year-over-year from -$4.2 million in Q1 2025.
Alvotech (ALVO) Capital Expenditures (2022 - 2026) Analysis & Trends
Alvotech's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$7.1 million for Q1 2026.
- Quarterly Capital Expenditures rose 69.2% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.5 million (up 183.12% YoY) and the FY2025 annual result came in at $64.5 million, up 20.14% from the prior year.
- Capital Expenditures was -$7.1 million for Q1 2026 at Alvotech, down from $120.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $120.2 million in Q4 2025 and bottomed at -$53.7 million in Q4 2024.
- A 5-year average of -$8.8 million and a median of -$13.6 million in 2025 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 324.0% in 2025, while the deepest fall reached 469.85% in 2025.
- Alvotech's Capital Expenditures stood at -$37.9 million in 2022, then climbed by 12.27% to -$33.2 million in 2023, then tumbled by 61.46% to -$53.7 million in 2024, then soared by 324.0% to $120.2 million in 2025, then sank by 105.94% to -$7.1 million in 2026.
- Business Quant data shows ALVO's Capital Expenditures at -$7.1 million in Q1 2026, $120.2 million in Q4 2025, and -$18.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | 99.60 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Alvotech | 924.10 Mn | 924.10 Mn | 5.09 Mn | -7.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.14 Mn |
| Mar 31, 2026 | -7.14 Mn |
| Dec 31, 2025 | 120.20 Mn |
| Dec 31, 2025 | 120.20 Mn |
| Sep 30, 2025 | -18.93 Mn |
| Sep 30, 2025 | -18.93 Mn |
| Jun 30, 2025 | -13.62 Mn |
| Jun 30, 2025 | -13.62 Mn |
| Mar 31, 2025 | -23.19 Mn |
| Mar 31, 2025 | -23.19 Mn |
| Dec 31, 2024 | -53.66 Mn |
| Dec 31, 2024 | -53.66 Mn |
| Sep 30, 2024 | -13.82 Mn |
| Sep 30, 2024 | -13.82 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Dec 31, 2023 | -33.23 Mn |
| Dec 31, 2023 | -33.23 Mn |